anti human trem1  (R&D Systems)

Journal: Cell

Article Title: SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis

doi: 10.1016/j.cell.2021.11.033

Figure Lengend Snippet:

Article Snippet: TREM1-PE , Miltenyi Biotec , Cat# 130-101-033, RRID: AB_2657706.

Techniques: Immunohistochemistry, Plasmid Preparation, Recombinant, Staining, Lysis, Protease Inhibitor, Mass Spectrometry, Sequencing, Modification, Bicinchoninic Acid Protein Assay, Enzyme-linked Immunosorbent Assay, Software

Journal: Glia

Article Title: Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cells

doi: 10.1002/glia.24252

Figure Lengend Snippet: Optimized liposome particles are strong triggering receptor expressed on myeloid cells 2 (TREM2) agonists. (a) phosphorylated‐spleen tyrosine kinase (p‐Syk) signal increase in TREM2‐DAP12 expressing human embryonic kidney (HEK) cell line (clone B1) upon antibody or liposome treatment. Starved B1 were stimulated for 5 min using AF1828 agonistic TREM2 antibody or indicated liposome formulations (F#1 to F#4 with percentage molar composition listed in left schema) at two concentrations (50 or 500 μg/ml). p‐Syk and total Syk levels were quantified in lysates using AlphaLISA kits. Each p‐Syk signal is normalized according to its corresponding total Syk signal. The induction signal plotted is the ratio of normalized p‐Syk signal for a treatment condition compared to vehicle treated cells. Data are presented as mean ± SD from four well/condition and were representative of three independent experiments. The same data format is used for panels B and C. (b) Kinetic of p‐Syk signal in AF1828 or liposome (formulation 3) treated B1 cells. Same protocol was used as in panel A but using an extended time course. (c) p‐Syk signal induction in TREM1‐Dap12 expressing HEK cell line (clone H). Cells were treated for 5 and 30 min using AF1278 TREM1 agonist antibody (10 μg/ml), AF1828 TREM2 antibody, or a concentration of 500 μg/ml of indicated liposome. CHO, cholesterol; DOPC, dioleoyl‐phosphocholine; DOPEG, dioleoyl‐phospho‐(ethylene glycol); DOPS, dioleoyl‐phospho‐L‐serine; DPPC, dipalmitoyl‐phosphocholine.

Article Snippet: The primary antibodies were obtained from the indicated providers: goat polyclonal anti‐hTREM2 (AF1828, R&D Systems), rabbit monoclonal anti‐hTREM2 (ab209814), rabbit monoclonal anti‐DAP12 (ab124834 Abcam), rabbit monoclonal anti‐APP (CST29765), rabbit monoclonal anti‐GAPDH (CST 5174), mouse monoclonal anti‐ β‐Actin (A2228, Sigma Aldrich), goat polyclonal anti‐hTREM1 (AF1278, R&D Systems), monoclonal mouse anti‐TREM1 (MAB1278, R&D Systems), goat polyclonal F(ab)2 IgG (H + L) PE‐conjugated Antibody (F0102B), monoclonal Mouse IgG1 anti‐human TREM‐1 PE‐conjugated Antibody (FAB1278P), monoclonal Rat IgG2B anti‐ Human/Mouse TREM2 PE‐conjugated Antibody (FAB17291P).

Techniques: Expressing, Formulation, Concentration Assay

Journal: Nature immunology

Article Title: Subsets of ILC3-ILC1-like cells generate a diversity spectrum of ILCs in human mucosal tissues.

doi: 10.1038/s41590-019-0425-y

Figure Lengend Snippet: a, The viSNE analysis of tonsil NKp44+ cells based on 36 selected markers and colored by intensity of expression. Each plot shows expression of the indicated cell surface marker. Populations corresponding to ILC3a, ILC3b, ILC1b and ILC1a are delineated in the CD127 plot. Cell subsets that lack CD103, but express CD94, NKG2A and CD127 are indicated as “Others”. b, Heat maps show graded expression of the indicated markers in the ILC subsets. Two donors analyzed in parallel on the same day are shown for consistency. c, The viSNE map of NKp44+CD103+ cells shows 3 clusters in which the degree of expression of CD127 and CCR6 inversely correlates with that of CD94. The viSNE analysis also identifies a small ILC1 cluster expressing CD16. Data are representative of six donors. Cells were gated based on NKp44 and CD161 (a,b) or NKp44, CD161 and CD103 (c) before running viSNE. Contaminating CD3+CD19+FceR+TREM1+CD14+ cells were excluded by manual gating.

Article Snippet: All the following antibodies were purchased from Fluidigm and included in the panel CD45–089Y (3089003B); CD196–141Pr (3141003A); CD19–142Nd (3142001B); CD117–143Nd (3143001B); CD4–145Nd (3145001B); CD8a-146Nd (3146001B); CD25–149Sm (3149010B); FceR-150Nd (3150027B); CD138–150Nd (3150012B); CD103–151Eu (3151011B); TCRgd-152Sm (3152008B); TIGIT-153Eu (3153019B); CD3–154Sm (3154003B); CD85j-156Gd (3156020B); CD194–158Gd (3158032A); CD161–159Tb (3159004B); CD39–160Gd (3160004B); CD27–162Dy (3162009B); CD45RO-165Ho (3165011B); CD34–166Er (3166012B); CD127–168Er (3168017B); CD159–169Tm (3169013B); CD45RA-170Er(3170010B); CD226–171Yb (3171013B); CD354(TREM1)-172Yb (3172022B); CD94–174Yb (3174015B); CD14–175Lu (3175015B); CD56–176Yb (3176009B) and CD16–299Bi (3209002B).

Techniques: Expressing, Marker